Immunogenicity and safety in healthy adults of full dose versus half doses of COVID-19 vaccine (ChAdOx1-S or BNT162b2) or full-dose CoronaVac administered as a booster dose after priming with CoronaVac: a randomised, observer-masked, controlled trial in Indonesia

Publication | Open Access

DOI Full Paper Access

Citations

References

2023

Year

Eddy Fadlyana, Djatnika Setiabudi, Cissy B. Kartasasmita, Nina Dwi Putri, Sri Rezeki Hadinegoro, Kim Mulholland, Yulia Sofiatin, Hendarsyah Suryadinata, Yovita Hartantri, Hadyana Sukandar,

The Lancet Infectious Diseases

VaccinologyVaccine SafetyVaccinationFull-dose CoronavacPreventive MedicineLong CovidVaccine SurveillanceCovid-19 PandemicVaccine EfficacyFull DoseCovid-19 EpidemiologyBooster DosePublic HealthMedicineVaccine HesitancyEpidemiologyCovid-19